Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efineptakin alfa + atezolizumab
- Development stage
- Unknown
- Lead developer
- NeoImmuneTech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intramuscular
01
Overview
**Efineptakin alfa + atezolizumab** is an investigational combination therapy comprised of efineptakin alfa (NT-I7), a novel long-acting recombinant human interleukin-7 cytokine, and atezolizumab (Tecentriq), a monoclonal antibody targeting programmed death-ligand 1 (PD-L1)[1][3][7]. Efineptakin alfa enhances T-cell amplification and function, potentially improving antitumor immune responses, while atezolizumab blocks PD-L1 to restore and potentiate T-cell-mediated antitumor activity[1][3][7]. The combination is under clinical investigation for advanced or metastatic solid tumors, with focus on high-risk skin cancers (melanoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma) and non-small cell lung cancer (NSCLC)[1][3][5][7].
- Brand names
- Tecentriq
- Other names
- human interleukin-7IL-7IL7IL 7NT-17NT17NT 17
02
Targets
IL7R (Interleukin-7 Receptor)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on efineptakin alfa + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efineptakin alfa + atezolizumab.